EVOLVE-MI: A Pragmatic Randomized Multicenter Trial of EVOLocumab Administered Very Early to Reduce the Risk of Cardiovascular Events in Patients Hospitalized With Acute Myocardial Infarction
EVOLVE-MI: A Pragmatic Randomized Multicenter Trial of EVOLocumab Administered Very Early to Reduce the Risk of Cardiovascular Events in Patients Hospitalized With Acute Myocardial Infarction
The primary objective of this study is to evaluate the effectiveness of early treatment with evolocumab plus routine lipid management vs routine lipid management alone when administered in the acute setting to reduce myocardial infarction, ischemic stroke, arterial revascularization, and all-cause death in subjects hospitalized for an acute myocardial infarction (non-ST-segment elevation myocardial infarction [NSTEMI] and ST-segment elevation myocardial infarction [STEMI]).
Inclusion Criteria:
Exclusion Criteria:
Flagstaff, Arizona 86001, United States
Charlotte, North Carolina 28204, United States
Powell, Tennessee 37849, United States
Ipiranga Goiânia, Goiás 74453-200, Brazil
Ipiranga Goiânia, Goiás 74453-200, Brazil
Belo Horizonte, Minas Gerais 30140-073, Brazil
Poços de Caldas, Minas Gerais 37706-106, Brazil
Porto Alegre, Rio Grande do Sul 90035-001, Brazil
Praia Comprida, Sao Jose, Santa Catarina 88103-450, Brazil
São Paulo, 05403-000, Brazil
Molndahl, 431 80, Sweden